Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > JMT202 (RECOMBINANT FULLY HUMAN ANTI-βKLOTHO MONOCLONAL ANTIBODY DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

JMT202 (RECOMBINANT FULLY HUMAN ANTI-βKLOTHO MONOCLONAL ANTIBODY DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

May 02, 2025

a250502a_00.png

Previous: SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Next: VOLUNTARY ANNOUNCEMENT - PIVOTAL PHASE II/III CLINICAL STUDY OF KN026 MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AT INTERIM ANALYSIS

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat